Bleomycin disposition in children with cancer
- PMID: 6188571
- DOI: 10.1038/clpt.1983.91
Bleomycin disposition in children with cancer
Abstract
Bleomycin kinetics were determined in 14 children after intravenous bolus and prolonged infusion doses. Plasma and urine bleomycin concentrations were determined by radioimmunoassay. After intravenous bolus, bleomycin concentrations were adequately described by a two-compartment open model with a mean t1/2 alpha and t1/2 beta of 0.3 +/- 0.1 and 3.2 +/- 0.7 hr (mean +/- SEM). Volume of the central compartment and volume of distribution at steady-state (Vss) were 4.3 +/- 0.5 and 9.9 +/- 1.1 l/m2. Total plasma (CLT) and renal (CLR) clearance were 51.8 +/- 6.1 and 33.5 +/- 2.4 ml/min/m2. Three intravenous bolus courses were given to two patients who received more than four courses of cisplatin (greater than 300 mg/m2); CLT and CLR for these courses were 18.0 +/- 3.3 and 8.2 ml/min/m2. Conversely, children under 3 yr old eliminated bleomycin more rapidly than older children. Decline in bleomycin concentrations after seven 24- or 48-hr intravenous infusions was described by a one-compartment model. Mean values for plasma t1/2, Vss, CLT, and CLR were 2.1 +/- 0.1 hr, 11.0 +/- 2.6 l/m2, 57.1 +/- 13.5 ml/min/m2, and 33.2 +/- 6.4 ml/min/m2. One patient received his bleomycin infusion when ureteral obstruction was present; CLT and CLR for this course were 4.8 and 4.1 ml/min/m2. These data indicate that young children eliminate bleomycin more rapidly than older children and that children with impaired renal function may have prolonged elevations in plasma concentration due to reduced bleomycin clearance. Bleomycin disposition in older children is as in adults.
Similar articles
-
Cisplatin-induced changes in bleomycin elimination.Cancer Treat Rep. 1983 Jun;67(6):587-9. Cancer Treat Rep. 1983. PMID: 6190560
-
Cefsulodin kinetics in renal impairment.Clin Pharmacol Ther. 1982 May;31(5):602-8. doi: 10.1038/clpt.1982.84. Clin Pharmacol Ther. 1982. PMID: 7075110
-
Clinical pharmacokinetics of vindesine infusion.Cancer Treat Rep. 1985 Jul-Aug;69(7-8):839-44. Cancer Treat Rep. 1985. PMID: 2410121
-
Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay.Cancer. 1977 Dec;40(6):2772-8. doi: 10.1002/1097-0142(197712)40:6<2772::aid-cncr2820400603>3.0.co;2-1. Cancer. 1977. PMID: 73408
-
Current status of American studies with bleomycin.Prog Biochem Pharmacol. 1976;11:158-71. Prog Biochem Pharmacol. 1976. PMID: 63960 Review. No abstract available.
Cited by
-
Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.Cancer Chemother Pharmacol. 1991;28(2):130-4. doi: 10.1007/BF00689702. Cancer Chemother Pharmacol. 1991. PMID: 2060084
-
High-performance liquid chromatography assay of bleomycin in human plasma and rat hepatocytes in culture.Cancer Chemother Pharmacol. 1991;28(1):22-6. doi: 10.1007/BF00684951. Cancer Chemother Pharmacol. 1991. PMID: 1710176
-
Predicting Organ-Specific Risk Interactions between Radiation and Chemotherapy in Secondary Cancer Survivors.Cancers (Basel). 2017 Sep 6;9(9):119. doi: 10.3390/cancers9090119. Cancers (Basel). 2017. PMID: 28878202 Free PMC article.
-
Pharmacokinetics of anticancer drugs in children.Clin Pharmacokinet. 1987 Mar;12(3):168-213. doi: 10.2165/00003088-198712030-00002. Clin Pharmacokinet. 1987. PMID: 3555940 Review.
-
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004. Clin Pharmacokinet. 1997. PMID: 9084960 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical